Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 03:00 ET | Source: AAVantgarde

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

LONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced...
October 07, 2025 16:00 ET | Source: AAVantgarde

AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting

MILAN, Oct. 07, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced three...
October 02, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutationAAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue...
September 05, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025

MILAN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today...
August 28, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025

MILAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today...
August 12, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

FDA grants Fast Track Designation to AAVantgarde's AAVB-039 gene therapy for Stargardt disease, advancing development for this rare cause of vision loss.
July 15, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

FDA clearance enables AAVantgarde's AAVB-039 to enter Phase 1/2 CELESTE trial in Stargardt disease, restoring robust ABCA4 expression.
May 12, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting

AAVantgarde presents positive Phase 1/2 safety data for Usher 1B and preclinical safety data for Stargardt at ARVO 2025, supporting future trials.
April 28, 2025 07:00 ET | Source: AAVantgarde

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

AAVantgarde Bio appoints Rasmus Holm-Jorgensen as CFO to support growth and advance AAV gene therapies for inherited retinal diseases.